PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Bradley M. Haverkos(University of Colorado Denver), Steven M. Devine(National Marrow Donor Program), Stacey Brown(Northside Hospital), Mehdi Hamadani(Medical College of Wisconsin), Mary E.D. Flowers(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Amitkumar Mehta(University of Alabama at Birmingham), Deborah M. Stephens(University of North Carolina at Chapel Hill), Yi‐Bin Chen(Massachusetts General Hospital), Parameswaran Hari(Medical College of Wisconsin), Robert Lowsky(Stanford University), Leslie A. Andritsos(University of New Mexico), Asad Bashey, Jonathan A. Gutman(University of Colorado Denver), Philippe Armand(Harvard University), Bruce R. Blazar(University of Minnesota Medical Center), Reid W. Merryman(Harvard University), Shin Mineishi(University of Alabama at Birmingham), Abraham S. Kanate(HonorHealth), Veronika Bachanová(University of Minnesota), Timothy S. Fenske(Medical College of Wisconsin), Madan Jagasia(Vanderbilt University Medical Center), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ryotaro Nakamura(City Of Hope National Medical Center), Manali Kamdar(University of Colorado Cancer Center), Diana Abbott(University of Colorado Anschutz Medical Campus), Siddhartha Ganguly(University of Kansas Medical Center)
Cited by 247
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
|Nature Medicine|2006|3.6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k